Drug Search Results
More Filters [+]

ICP-B02

Alternative Names: ICP-B02, ICPB02, ICP B02, CM355, CM-355
Latest Update: 2024-08-20
Latest Update Note: News Article

Product Description

Innocare is developing ICP-B02, a CD3 x CD20 for hematology. (Sourced from: https://www.innocarepharma.com/media/1602/innocare-interim-ndr_en_2021829_final-de.pdf)

Mechanisms of Action: CD20 Antagonist,CD3 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Innocare Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ICP-B02

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CM355-001

P2

Active, not recruiting

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2026-12-28

31%

CM355-001

P2

Active, not recruiting

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2026-12-28

31%

Recent News Events